Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation
Petkovic A., Al-Khalili F., Antovic A., Ammar M., Pruner I., Vranic A., Soutari N., Zdravkovic N., Malmström R. E., Yakovlevich V., Antovic J. P.
Blood Coagulation and Fibrinolysis
Vol.31, Issue4, P. 243-252
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.1097/MBC.0000000000000907
Аннотация:
The study was aimed to evaluate the effects of two standard doses of rivaroxaban and dabigatran on global hemostatic assays in patients with atrial fibrillation. The study included 52 patients treated with rivaroxaban (15/20 mg), 50 on dabigatran (110/150 mg) and 20 healthy individuals. Platelet-poor plasma was used for determination of three global hemostatic assays, namely endogenous thrombin potential (ETP), calibrated automated thrombogram (CAT) and overall hemostasis potential (OHP). Rivaroxaban and dabigatran reduced ETP (P < 0.01) although OHP (P < 0.05) was diminished only by dabigatran. Strong correlations were noticed between ETP parameters and the plasma concentrations of rivaroxaban (ETP, r = -0.51; c-max, r = -0.85; t-lag, r = 0.83; t-max, r = 0.66) as well as with plasma concentration of dabigatran (ETP, r = -0.75; c-max, r = -0.74; t-lag, r = 0.73; t-max, r = 0.52). Analysis of dabigatran concentrations under 50 ng/ml showed that ETP parameter has area under the concentr
Ключевые слова:
atrial fibrillation; dabigatran; endogenous thrombin potential; overall hemostatic potential; rivaroxaban
Язык текста: Английский
ISSN: 1473-5733
Petkovic A.
Al-Khalili F.
Antovic A.
Ammar M.
Pruner I.
Vranic A.
Soutari N.
Zdravkovic N.
Malmström R. E.
Yakovlevich V. Vladimir 1971-
Antovic J. P.
Петковиc А.
Ал-Халили Ф.
Антовиc А.
Аммар М.
Прунер И.
Враниc А.
Соутари Н.
Здравковиc Н.
Малмстрöм Р. Е.
Яковлевич В. Владимир 1971-
Антовиc Й. П.
Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation
Текст визуальный непосредственный
Blood Coagulation and Fibrinolysis
Lippincott Williams & Wilkins
Vol.31, Issue4 P. 243-252
2020
Статья
atrial fibrillation dabigatran endogenous thrombin potential overall hemostatic potential rivaroxaban
The study was aimed to evaluate the effects of two standard doses of rivaroxaban and dabigatran on global hemostatic assays in patients with atrial fibrillation. The study included 52 patients treated with rivaroxaban (15/20 mg), 50 on dabigatran (110/150 mg) and 20 healthy individuals. Platelet-poor plasma was used for determination of three global hemostatic assays, namely endogenous thrombin potential (ETP), calibrated automated thrombogram (CAT) and overall hemostasis potential (OHP). Rivaroxaban and dabigatran reduced ETP (P < 0.01) although OHP (P < 0.05) was diminished only by dabigatran. Strong correlations were noticed between ETP parameters and the plasma concentrations of rivaroxaban (ETP, r = -0.51; c-max, r = -0.85; t-lag, r = 0.83; t-max, r = 0.66) as well as with plasma concentration of dabigatran (ETP, r = -0.75; c-max, r = -0.74; t-lag, r = 0.73; t-max, r = 0.52). Analysis of dabigatran concentrations under 50 ng/ml showed that ETP parameter has area under the concentr